-Celox? works independently to body?s normal blood clotting mechanism. Unlike other hemostatic agents, it therefore continues to work when normal clotting is impaired such as in the potentially hypothermic conditions present during Medevac. It even continues to clot blood in extreme cold or when anticoagulants such as Coumadin or Heparin are present.
-Celox? technology also has an excellent safety profile. It uses chitosan, a natural polysaccharide (complex sugar) which:
-has over a decade of history in human clinical use in contact with blood vessels and a great long term safety profile.
-does not generate heat, and therefore gives no risk of burning.
-only clots the blood it comes into contact with and so does not initiate a wider or more generalised clotting response.
-is broken down in the body by lysozyme, a human enzyme, to leave glucosamine, a sugar which is normally found in the body***.
Celox? does not use or release any fine dispersing procoagulant minerals or alumina based clays such as smectitie or kaolin, which:
-do not have an equivalent history of human clinical use in contact with blood vessels.
initiate a more generalised clotting response.
-will remain in the body indefinately unless completely removed.